SNY Stock Analysis Today

Updated Nov 15, 2026 · trends, key levels, insider activity and news

$48.37-$0.09 (-0.19%)close Nov 13, 2026

Is SNY bullish or bearish today?

Daily trend: Downtrend (confirmed) — turns up above $40.31

SEPT signal: Institutional Drive · Strong Bullish

Research grade: C+ · fair value $71.73

SNY trend by timeframe

DailyDowntrend (confirmed)
4 hourLeaning Bearish
1 hourBearish
15 minBearish
5 minLeaning Bearish

Trends are calculated from price structure and update during market hours.

SNY support and resistance levels

Resistance (above)

$49.428 touches

$50.604 touches

$51.601 touches

Support (below)

$47.8823 touches

$46.891 touches

$45.5816 touches

Upside zones: $45.83 / $46.10 / $46.37

See all levels on the live chart →

Insider and institutional activity

Insiders

Neutral

30-day buys / sells

0 / 0

30-day net

—

Hedge fund holders

0

Latest SNY news and filings

  • DealFiscal.ai

    Sanofi to buy Vicebio and Dynavax in $3.4 billion deal

    Sanofi is purchasing Vicebio and Dynavax, with the transaction valued at $3.4 billion. Both businesses will become part of Sanofi.

  • DealFiscal.ai

    Sanofi Pays MacroGenics $24.5 Million After Milestone

    MacroGenics said Sanofi paid it $24.5 million tied to a milestone. The payment stems from the two drugmakers' existing agreement.

  • DealFiscal.ai

    Sanofi adds equity investment in Adagene trial

    Sanofi has made a further equity investment tied to an Adagene trial. The move adds to Sanofi's existing financial backing of the study.

  • AnalystFiscal.ai

    UBS lifts its price target on Sanofi

    UBS raised its price target for Sanofi. The change is an analyst update on the drugmaker's stock.

  • AnalystFiscal.ai

    BNP Paribas raises Sanofi rating to Outperform

    BNP Paribas upgraded Sanofi's stock rating to Outperform. The change reflects the analyst's updated view of the company.

  • AnalystFiscal.ai

    AlphaValue/Baader Europe raises its price target on Sanofi

    AlphaValue/Baader Europe increased its price target for Sanofi. The change is an analyst update and does not include a stated reason or new figure.

  • AnalystFiscal.ai

    AlphaValue/Baader Europe raises Sanofi rating to Add

    AlphaValue/Baader Europe upgraded its rating on Sanofi to Add. The change reflects the firm's revised view of the drugmaker's shares.

All SNY news from the last 90 days →
SEPT InvestingBeta Pioneer $29.99/mo until Jan 2, 2027

Live SNY chart with trend icons on every timeframe, key levels, dark pool and options flow, news alerts, and Ask GOAX for a full analysis on demand.

Start free 7-day trial

Frequently asked questions

Is SNY bullish or bearish today?

SNY daily trend: Downtrend (confirmed) — turns up above $40.315. SEPT signal: Institutional Drive (Strong Bullish). Updated Nov 15, 2026.

What is SNY's trend on each timeframe?

Daily: Downtrend (confirmed); 4 hour: Leaning Bearish; 1 hour: Bearish; 15 min: Bearish; 5 min: Leaning Bearish.

What are SNY support and resistance levels?

Support: $47.88, $46.89, $45.58. Resistance: $49.42, $50.60, $51.60. Last price $48.37.

Are insiders buying or selling SNY?

Insider signal: Neutral. Last 30 days: 0 buys, 0 sells.

What is the latest news on SNY?

Nov 13, 2026: Sanofi to buy Vicebio and Dynavax in $3.4 billion deal · Nov 13, 2026: Sanofi Pays MacroGenics $24.5 Million After Milestone · Nov 9, 2026: Sanofi adds equity investment in Adagene trial